Reactivation of latent Epstein-Barr virus by methotrexate: A potential contributor to methotrexate-associated lymphomas

Journal of the National Cancer Institute

Volumn 96, Issue 22, 2004, Pages 1691-1702

  Feng, Wen Hai ^a   Cohen, Jeffrey I ^b   Fischer, Steven ^d   Li, Li ^d   Sneller, Michael ^b   Goldbach Mansky, Raphael ^c   Raab Traub, Nancy ^a   Delecluse, Henri Jacques ^e   Kenney, Shannon C ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^d NATIONAL INSTITUTES OF HEALTH   (United States)

^e GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 2 MORPHOLINO 8 PHENYLCHROMONE; 4 (4 FLUOROPHENYL) 2 (4 HYDROXYPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; ACICLOVIR; AZATHIOPRINE; CISPLATIN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; DOXORUBICIN; ETANERCEPT; FLUOROURACIL; GEMCITABINE; HYDROXYCHLOROQUINE; LEFLUNOMIDE; METHOTREXATE; MITOGEN ACTIVATED PROTEIN KINASE P38; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; VIRUS DNA;

ARTICLE; BLOOD SAMPLING; CANCER CELL CULTURE; CLINICAL ARTICLE; CONFIDENCE INTERVAL; CONTROLLED STUDY; DRUG METABOLISM; EPSTEIN BARR VIRUS; GENE AMPLIFICATION; GENE SEQUENCE; HUMAN; HUMAN CELL; IN VITRO STUDY; LYMPHOBLASTOID CELL LINE; POLYMYOSITIS; PRIORITY JOURNAL; REPORTER GENE; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; STOMACH CARCINOMA; VIRUS ACTIVATION; VIRUS LOAD; VIRUS REACTIVATION; VIRUS TRANSCRIPTION; WEGENER GRANULOMATOSIS;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ARTHRITIS, RHEUMATOID; CELL LINE, TUMOR; DNA, VIRAL; EPSTEIN-BARR VIRUS INFECTIONS; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE EXPRESSION REGULATION, VIRAL; HERPESVIRUS 4, HUMAN; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LYMPHOMA; MAP KINASE KINASE KINASES; METHOTREXATE; P38 MITOGEN-ACTIVATED PROTEIN KINASES; POLYMERASE CHAIN REACTION; POLYMYOSITIS; PROMOTER REGIONS (GENETICS); SIGNAL TRANSDUCTION; VIRAL LOAD;

EID: 9744256149     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/djh313     Document Type: Article

References (63)

1. Kieff, E. Epstein-Barr virus and its replication. In: Knipe D, Howley P, editors. Fields virology. 4th ed. Philadelphia (PA): Lippincott-Raven; 2001. p. 2511-74.
2. Rickinson AB, Kieff E. Epstein-Barr virus. In: Knipe D, Howley P, editors. Fields virology, 4th ed. Philadelphia (PA): Lippincott-Raven; 2001. p. 2575-627.
3. Cohen JI. Epstein-Barr virus infection. N Engl J Med 2000;343:481-92.
4. Kamel OW, van de Rijn M, Weiss LM, Del Zoppo GJ, Hench PK, Robbins BA, et al. Brief report: reversible lymphomas associated with Epstein-Barr virus occurring during methotrexate therapy for rheumatoid arthritis and dermatomyositis. N Engl J Med 1993;328:1317-21.
5. Salloum E, Cooper DL, Howe G, Lacy J, Tallini G, Crouch J, et al. Spontaneous regression of lymphoproliferative disorders in patients treated with methotrexate for rheumatoid arthritis and other rheumatic diseases. J Clin Oncol 1996;14:1943-9.
6. Georgescu L, Quinn GC, Schwartzman S, Paget SA. Lymphoma in patients with rheumatoid arthritis: association with the disease state or methotrexate treatment. Semin Arthritis Rheum 1997;26:794-804.
7. Kojima M, Nakamura S, Futamura N, Kurabayashi Y, Ban S, Itoh H, et al. Malignant lymphoma in patients with rheumatic diseases other than Sjogren's syndrome: a clinicopathologic study of five cases and a review of the Japanese literature. Jpn J Clin Oncol 1997;27:84-90.
8. Birx DL, Redfield RR, Tosato G. Defective regulation of Epstein-Barr virus infection in patients with acquired immunodeficiency syndrome (AIDS) or AIDS-related disorders. N Engl J Med 1986;314:874-9.
9. Riddler SA, Breinig MC, McKnight JL. Increased levels of circulating Epstein-Barr virus (EBV)-infected lymphocytes and decreased EBV nuclear antigen antibody responses are associated with the development of posttransplant lymphoproliferative disease in solid-organ transplant recipients. Blood 1994;84:972-84.
10. Jenson H, McIntosh K, Pitt J, Husak S, Tan M, Bryson Y, et al. Natural history of primary Epstein-Barr virus infection in children of mothers infected with human immunodeficiency virus type 1. J Infect Dis 1999; 179:1395-404.
11. van Esser JW, van der Holt B, Meijer E, Niesters HG, Trenschel R, Thijsen SF, et al. Epstein-Barr virus (EBV) reactivation is a frequent event after allogeneic stem cell transplantation (SCT) and quantitatively predicts EBV-lymphoproliferative disease following T-cell-depleted SCT. Blood 2001; 98:972-8.
12. Stevens SJ, Blank BS, Smits PH, Meenhorst PL, Middeldorp JM. High Epstein-Barr virus (EBV) DNA loads in HIV-infected patients: correlation with antiretroviral therapy and quantitative EBV serology. AIDS 2002;16: 993-1001.
13. Hanto DW, Frizzera G, Gajl-Peczalska KJ, Sakamoto K, Purtilo DT, Balfour HH Jr, et al. Epstein-Barr virus-induced B-cell lymphoma after renal transplantation: acyclovir therapy and transition from polyclonal to monoclonal B-cell proliferation. N Engl J Med 1982;306:913-8.
14. Morrison VA, Dunn DL, Manivel JC, Gajl-Peczalska KJ, Peterson BA. Clinical characteristics of post-transplant lymphoproliferative disorders. Am J Med 1994;97:14-24.
15. Darenkov IA, Marcarelli MA, Basadonna GP, Friedman AL, Lorber KM, Howe JG, et al. Reduced incidence of Epstein-Barr virus-associated post-transplant lymphoproliferative disorder using preemptive antiviral therapy. Transplantation 1997;64:848-52.
16. McDiarmid SV, Jordan S, Kim GS, Toyoda M, Goss JA, Vargas JH, et al. Prevention and preemptive therapy of postransplant lymphoproliferative disease in pediatric liver recipients. Transplantation 1998;66:1604-11.
17. Prior P. Cancer and rheumatoid arthritis: epidemiologic considerations. Am J Med 1985;78:15-21.
18. Gridley G, McLaughlin JK, Ekbom A, Klareskog L, Adami HO, Hacker DG, et al. Incidence of cancer among patients with rheumatoid arthritis. J Natl Cancer Inst 1993;85:307-11.
19. Kamel OW, van de Rijn M, LeBrun DP, Weiss LM, Warnke RA, Dorfman RF. Lymphoid neoplasms in patients with rheumatoid arthritis and dermatomyositis: frequency of Epstein-Barr virus and other features associated with immunosuppression. Hum Pathol 1994;25:638-43.
20. Kamel OW, Weiss LM, van de Rijn M, Colby TV, Kingma DW, Jaffe ES. Hodgkin's disease and lymphoproliferations resembling Hodgkin's disease in patients receiving long-term low-dose methotrexate therapy. Am J Surg Pathol 1996;20:1279-87.
21. Menke DM, Griesser H, Moder KG, Tefferi A, Luthra HS, Cohen MD, et al. Lymphomas in patients with connective tissue disease. Comparison of p53 protein expression and latent EBV infection in patients immunosuppressed and not immunosuppressed with methotrexate. Am J Clin Pathol 2000;113:212-8.
22. Liote F, Pertuiset E, Cochand-Priollet B, D'Agay MF, Dombret H, Numeric P, et al. Methotrexate related B lymphoproliferative disease in a patient with rheumatoid arthritis. Role of Epstein-Barr virus infection. J Rheumatol 1995;22:1174-8.
23. Bachman TR, Sawitzke AD, Perkins SL, Ward JH, Cannon GW. Methotrexate-associated lymphoma in patients with rheumatoid arthritis: report of two cases. Arthritis Rheum 1996;39:325-9.
24. Thomason RW, Craig FE, Banks PM, Sears DL, Myerson GE, Gulley ML. Epstein-Barr virus and lymphoproliferation in methotrexate-treated rheumatoid arthritis. Mod Pathol 1996;9:261-6.
25. Feng WH, Israel B, Raab-Traub N, Busson P, Kenney SC. Chemotherapy induces lytic EBV replication and confers ganciclovir susceptibility to EBV-positive tumors. Cancer Res 2002;62:1920-6.
26. Feng WH, Hong G, Delecluse HJ, Kenney SC. Lytic induction therapy for Epstein-Barr virus-positive B-cell lymphomas. J Virol 2004;78:1893-902.
27. Feederle R, Kost M, Baumann M, Janz A, Drouet E, Hammerschmidt W, et al. The Epstein-Barr virus lytic program is controlled by the co-operative functions of two transactivators. EMBO J 2000;19:3080-9.
28. Adamson AL, Kenney SC. Rescue of the Epstein-Barr Virus BZLF1 mutant, Z(S186A), early gene activation defect by the BRLF1 gene product. Virology 1998;251:187-97.
29. Zalani S, Holley-Guthrie EA, Gutsch DE, Kenney SC. The Epstein-Barr virus immediate-early promoter BRLF1 can be activated by the cellular Sp1 transcription factor. J Virol 1992;66:7282-9.
30. Zalani S, Holley-Guthrie E, Kenney S. The Zif268 cellular transcription factor activates expression of the Epstein-Barr virus immediate-early BRLF1 promoter. J Virol 1995;69:3816-23.
31. Flemington E, Speck SH. Identification of phorbol ester response elements in the promoter of Epstein-Barr virus putative lytic switch gene BZLF1. J Virol 1990;64:1217-26.
32. Speck SH, Chatila T, Flemington, E. Reactivation of Epstein-Barr virus: regulation and function of the BZLF1 gene. Trends Microbiol 1997;5:399-405.
33. Gorman C, Moffat L, Howard B. Recombinant genomes which express chloramphenicol acetyl transferase in mammalian cells. Mol Cell Biol 1982;2:1044-51.
34. Raab-Traub N, Flynn K. The structure of the termini of the Epstein-Barr virus as a marker of clonal cellular proliferation. Cell 1986;47:883-9.
35. Baer R, Bankier AT, Biggin MD, Deininger PL, Farrell PJ, Gibson TJ, et al. DNA sequence and expression of the B95-8 Epstein-Barr virus genome. Nature 1984;310:207-11.
36. Adamson AL, Darr D, Holley-Guthrie E, Johnson RA, Mauser A, Swenson J, et al. Epstein-Barr virus immediate-early proteins BZLF1 and BRLF1 activate the ATF2 transcription factor by increasing the levels of phosphorylated p38 and c-Jun N-terminal kinases. J Virol 2000;74:1224-33.
37. Fahmi H, Cochet C, Hmama Z, Opolon P, Joab I. Transforming growth factor beta 1 stimulates expression of the Epstein-Barr virus BZLF1 immediate-early gene product ZEBRA by an indirect mechanism which requires the MAPK kinase pathway. J Virol 2000;74:5810-8.
38. Darr CD, Mauser A, Kenney S. Epstein-Barr virus immediate-early protein BRLF1 induces the lytic form of viral replication through a mechanism involving phosphatidylinositol-3 kinase activation. J Virol 2001;75:6135-42.
39. Bryant H, Farrell PJ. Signal transduction and transcription factor modification during reactivation of Epstein-Barr virus from latency. J Virol 2002;76:10290-8.
40. Borras AM, Strominger JL, Speck SH. Characterization of the ZI domains in the Epstein-Barr virus BZLF1 gene promoter: role in phorbol ester induction. J Virol 1996;70:3894-901.
41. Liu S, Liu P, Borras A, Chatila T, Speck SH. Cyclosporin A-sensitive induction of the Epstein-Barr virus lytic switch is mediated via a novel pathway involving a MEF2 family member. EMBO J 1997;16:143-53.
42. Wang YC, Huang JM, Montalvo EA. Characterization of proteins binding to the ZII element in the Epstein-Barr virus BZLF1 promoter: transactivation by ATF1. Virology 1997;227:323-30.
43. Niesters HG, van Esser J, Fries E, Wolthers KC, Cornelissen J, Osterhaus AD. Development of a real-time quantitative assay for detection of Epstein-Barr virus. J Clin Microbiol 2000;38:712-5.
44. Tosato G, Steinberg AD, Blaese RM. Defective EBV-specific suppressor T-cell function in rheumatoid arthritis. N Engl J Med 1981;305:1238-43.
45. Kahan A, Kahan A, Amor B, Menkes CJ. Different defects of T cell regulation of Epstein-Barr virus-induced B cell activation in rheumatoid arthritis. Arthritis Rheum 1985;28:961-70.
46. Tosato G, Steinberg AD, Yarchoan R, Heilman CA, Pike SE, De Seau V, et al. Abnormally elevated frequency of Epstein-Barr virus-infected B cells in the blood of patients with rheumatoid arthritis. J Clin Invest 1984;73: 1789-95.
47. Gridley G, Klippel JH, Hoover RN, Fraumeni JF Jr. Incidence of cancer among men with the Felty syndrome. Ann Intern Med 1994;120:35-9.
48. Baecklund E, Ekbom A, Sparen P, Feltelius N, Klareskog L. Disease activity and risk of lymphoma in patients with rheumatoid arthritis: nested case-control study. BMJ 1998;317:180-1.
49. Balandraud N, Meynard JB, Auger I, Sovran H, Mugnier B, Reviron D, et al. Epstein-Barr virus load in the peripheral blood of patients with rheumatoid arthritis: accurate quantification using real-time polymerase chain reaction. Arthritis Rheum 2003;48:1223-1228.
50. zur Hausen H, O'Neill FJ, Freese UK, Hecker E. Persisting oncogenic herpesvirus induced by the tumour promotor TPA. Nature 1978;272:373-5.
51. Faggioni A, Zompetta C, Grimaldi S, Barile G, Frati L, Lazdins J. Calcium modulation activates Epstein-Barr virus genome in latently infected cells. Science 1986;232:1554-6.
52. Luka J, Kallin B, Klein G. Induction of the Epstein-Barr virus (EBV) cycle in latently infected cells by n-butyrate. Virology 1979;94:228-31.
53. Westphal EM, Blachstock W, Feng WH, Israel B, Kenney SC. Activation of lytic Epstein-Barr virus (EBV) infection by radiation and sodium butyrate in vitro and in vivo: a potential method for treating EBV-positive malignancies. Cancer Res 2000;60:5781-8.
54. Takata K. Cross-linking of cell surface immunoglobulins induces Epstein-Barr virus in Burkitt lymphoma lines. Int J Cancer 1984;33:27-32.
55. Moore SM, Cannon JS, Tanhehco YC, Hamzeh FM, Ambinder RF. Induction of Epstein-Barr virus kinases to sensitize tumor cells to nucleoside analogues. Antimicrob Agents Chemother 2001;45:2082-91.
56. Countryman J, Miller G. Activation of expression of latent Epstein-Barr herpesvirus after gene transfer with a small cloned subfragment of heterogeneous viral DNA. Proc Natl Acad Sci U S A 1985;82:4085-9.
57. Zalani S, Holley-Guthrie E, Kenney S. Epstein-Barr viral latency is disrupted by the immediate-early BRLF1 protein through a cell-specific mechanism. Proc Natl Acad Sci U S A 1996;93:9194-9.
58. van Dam H, Wilhelm D, Herr I, Steffen A, Herrlich P, Angel P. ATF-2 is preferentially activated by stress-activated protein kinases to mediate c-jun induction in response to genotoxic agents. EMBO J 1995;14:1798-811.
59. Livingstone C, Patel G, Jones N. ATF-2 contains a phosphorylation-dependent transcriptional activation domain. EMBO J 1995;14:1785-97.
60. Zhao M, New L, Kravchenko VV, Kato Y, Gram H, di Padova F, et al. Regulation of the MEF2 family of transcription factors by p38. Mol Cell Biol 1999;19:21-30.
61. Arai M, Yoguchi A, Takizawa T, Yokoyama T, Kanda T, Kurabayashi M, et al. Mechanism of doxorubicin-induced inhibition of sarcoplasmic reticulum Ca(2+)-ATPase gene transcription. Circ Res 2000;86:8-14.
62. Lim CP, Jain N, Cao X. Stress-induced immediate-early gene, egr-1, involves activation of p38/JNK1. Oncogene 1998;16:2915-26.
63. Mariette X, Cazals-Hatem D, Warszawki J, Liote F, Balandraud N, Sibilia J, et al. Lymphomas in rheumatoid arthritis patients treated with methotrexate: a 3-year prospective study in France. Blood 2002; 99: 3909-15.